Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which …
Full ILMN analysis →
Competitive advantage assessment
Key strengths
Elite Gross MarginsGross margin quality is top-tier vs peers (score 0.82). This signals strong consumable attach-rate economics.
Strong FCF GenerationFCF margin quality is top-tier vs peers (score 0.93). High FCF conversion confirms strong earnings quality.
Key risks
Elevated LeverageLeverage is elevated vs peers (score 0.34). High net debt/EBITDA limits the balance sheet's acquisition firepower.
Revenue Growth SlowingRevenue growth trend is weak (score 0.31). Slowing top-line momentum reduces the future consumable base.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Illumina, Inc. ranks #5 of 62
scored companies in Diagnostics & Research by moat score — the top 8%.
The widest moat in the group is IDEXX Laboratories, Inc. (IDXX)
at 78/100.
Moat scores for companies ranked near ILMN in Diagnostics & Research
How ILMN scores on the Medical Devices & Diagnostics defenses
Pricing Power & Consumable Moat
Score 72
· 25% of the moat score
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.
R&D Pipeline & Capital Returns
Score 68
· 20% of the moat score
Research spending is how a device company keeps its installed base current, but spending alone proves nothing.
FCF Quality & Cash Conversion
Score 78
· 20% of the moat score
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.
Commercial Execution
Score 81
· 15% of the moat score
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.
Capital Structure & Resilience
Score 60
· 12% of the moat score
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.
Growth Durability
Score 59
· 8% of the moat score
Growth durability separates an expanding installed base from a good product cycle.
Illumina, Inc. (ILMN) scores 71 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #5 of 62 scored companies in Diagnostics & Research, the top 8%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Diagnostics & Research. Its strongest defense is Commercial Execution (81/100) and its weakest is Growth Durability (59/100).
How does Illumina, Inc. compare with other Diagnostics & Research companies?
Illumina, Inc. ranks #5 of 62 scored companies in Diagnostics & Research by moat score. The widest moat in Diagnostics & Research is IDEXX Laboratories, Inc. (IDXX) at 78/100. The companies ranked closest are Danaher Corporation (DHR) at 72 just above it and Waters Corporation (WAT) at 71 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Diagnostics & Research. The defenses are then weighted to produce the overall score out of 100.
Why is Illumina, Inc. scored with the Medical Devices & Diagnostics template?
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
Which competitive defenses are measured for Illumina, Inc.?
The Medical Devices & Diagnostics template measures 6 defenses, and ILMN scores: Pricing Power & Consumable Moat (72), R&D Pipeline & Capital Returns (68), FCF Quality & Cash Conversion (78), Commercial Execution (81), Capital Structure & Resilience (60), Growth Durability (59). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.